Osteonecrosis of the jaw related to sunitinib.
METHODS
A 59-year-old male patient was referred to the hospital with exposed bone measuring 10 mm in diameter in the posterior, left-side region of the lower jaw. Two months previous, the first molar had been extracted. The patient had contracted renal cell carcinoma and had been treated by nephrectomy in 2003. Soft tissue metastases occurred. After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by sunitinib. Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib.


CONCLUSIONS
Bisphosphonates had never been applied. With increasing application of multi-kinase inhibitors, complications due to osteonecrosis could occur more frequently.
Koch
Felix P
FP
Oral and Maxillofacial Surgery, University Medical Centre of the Johannes Gutenberg University, Mund-, Kiefer-und Gesichtschirurgie, Mainz, Germany. koch@mkg.klinik.uni-mainz.de
Walter
Christian
C
Hansen
Torsten
T
Jäger
Elke
E
Wagner
Wilfried
W
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D008875:Middle Aged; D008963:Molar / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000601:surgery; D009392:Nephrectomy; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D011183:Postoperative Complications / Q000139:chemically induced / Q000175:diagnosis / Q000601:surgery; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D014081:Tooth Extraction
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
Oncology. 2009;76(3):209-11
19212145
Support Care Cancer. 2007 Feb;15(2):197-202
16941133
Support Cancer Ther. 2006 Jan 1;3(2):122-4
18632450
Eur J Clin Pharmacol. 1992;42(5):545-7
1607002
Curr Pharm Des. 2004;10(16):1867-83
15180525
Eur Urol. 2008 Nov;54(5):1066-72
18602738
Am J Pathol. 1993 Nov;143(5):1377-88
8238254
Oral Maxillofac Surg. 2010 Mar;14(1):3-16
20119841
Arch Dermatol. 2008 Jan;144(1):123-5
18209189
Clin Cancer Res. 2003 Jan;9(1):327-37
12538485
J Clin Oncol. 2006 Jan 1;24(1):16-24
16330672
Acta Microbiol Acad Sci Hung. 1981;28(3):257-62
6171139
J Clin Oncol. 2006 Jan 1;24(1):25-35
16314617
J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
16002463
Head Neck Surg. 1982 Jan-Feb;4(3):251-3
6896046
J Oral Maxillofac Surg. 2004 Feb;62(2):125-6
14762742
Curr Clin Pharmacol. 2008 May;3(2):132-43
18690886
Curr Treat Options Oncol. 2007 Jun;8(3):211-26
17712534
Ann Oncol. 2009 Mar;20(3):600-1
19188135
J Clin Oncol. 2002 Mar 15;20(6):1692-703
11896121
Bone. 2009 Jan;44(1):173-5
18849018
Virchows Arch. 2007 Dec;451(6):1009-17
17952459
Can Urol Assoc J. 2007 Jun;1(2 Suppl):S41-54
18542784
J Clin Oncol. 2007 Mar 1;25(7):884-96
17327610
Mund Kiefer Gesichtschir. 2006 Sep;10(5):287-300
16960697
N Engl J Med. 2007 Apr 12;356(15):1580; author reply 1580-1
17429091